"If I'm going to subject my patient to an implanted device, the incremental risk of adding a CRT, rather than just a primary prevention defibrillator, are worth it."

William Abraham, MD, director of the division of cardiovascular medicine at Ohio State University Medical Center (Columbus), "ICD market may expand on news from REVERSE trial," pp. 1, 7.